Cardiac organoids closely mimic the cellular composition of the human heart, offering an accurate representation of cardiac responses.
This fidelity allows for early identification of adverse effects, effectively preventing the progression of toxic candidates in drug development.
Moreover, these organoids facilitate the study of toxicity within the context of specific cardiac diseases.
The personalized nature of toxicity assessments is enhanced, considering individual genetic variations in drug responses.
This holistic approach significantly improves our understanding of drug safety and efficacy.